During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4

Journal of Neuroimmunology

Volumn 177, Issue 1-2, 2006, Pages 161-166

  Basile, Erika ^a   Gibbs, Ebrima ^a   Aziz, Tariq ^a   Oger, Joel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti GA antibodies; Glatiramer acetate; IgG in serum; IgG secretion in vitro; IgG1 IgG2 IgG3 IgG4; Primary progressive multiple sclerosis; Th1 Th2

Indexed keywords

GLATIRAMER; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PLACEBO; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; ANTIBODY SPECIFICITY; BLOOD; CELL CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; IMMUNOLOGY; LONGITUDINAL STUDY; MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH2 CELL; TIME; UPREGULATION;

ANTIBODY SPECIFICITY; CELLS, CULTURED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PEPTIDES; TH1 CELLS; TH2 CELLS; TIME FACTORS; UP-REGULATION;

EID: 33746294679     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.04.024     Document Type: Article

References (32)

1. Aharoni R., Teitelbaum D., Sela M., and Arnon R. Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10821-10826
2. 2 type induced by copolymer 1. J. Neuroimmunol. 91 (1998) 135-146
3. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate specific T cells in the brain express T helper 2/3 cytokines and brainderived neurotrophic factor in situ. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14157-14162
4. Brenner T., Arnon R., Sela M., et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone®. J. Neuroimmunol. 115 (2001) 152-160
5. 2-biased response and cross-reactivity with myelin basic protein. Mult. Scler. 7 (2001) 209-219
6. Chen M., Conway K., Johnson K.P., Marin R., and Dhib-Jalbut R. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J. Neurol. Sci. 201 1-2 (2002) 71-77
7. Chen M., Valenzuela R.M., and Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol. Sci. 215 (2003) 37-44
8. 2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105 (2000) 967-976
9. Duran I., Martinez-Caceres M., Rio J., Barbera N., Marzo E., and Montalban X. Immunological profile of patients with primary progressive multiple sclerosis. Brain 122 (1999) 2297-2307
10. Farina C., Then Bergh F., Albrecht H., Meinl E., Yassouridis A., Neuhaus O., and Hohlfeld R. Treatment of multiple sclerosis with Copaxone (COP): elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 124 (2001) 705-719
11. Farina C., Vargas V., Heydari N., Kumpful T., Meinl E., and Hohlfeld R. Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients. J. Neuroimmunol. 123 (2002) 188-192
12. Gran B., Tranquill L.R., Chen M., et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55 (2000) 1704-1714
13. 2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 55 4 (1999) 1198
14. Johnson, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blinded, placebo-controlled trial. Neurology 45 (1995) 1268-1276
15. Killestein J., Den Drijver B.F., Van der Graaff W.L., Uitdehaag B.M., Polman C.H., and Van Lier R.A. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult. Scler. 3 (2001) 145-150
16. Kim H.J., Biernacki K., Prat A., Antel J.P., and Bar-Or A. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clin. Immunol. 111 (2004) 38-46
17. Kimata H., Yoshida A., Ishioka C., Kusunoki T., Hosoi S., and Mikawa H. Nerve growth factor specifically induces human IgG4 production. Eur. J. Immunol. 21 (1991) 137-141
18. McDonnell G., McMillan S., Douglas J., Droogan A., and Hawkins S. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease. J. Neurol. 246 (1999) 87-92
19. Martin R., Sturzebecher C.S., and McFarland H.F. Immunotherapy of multiple sclerosis: where are we? Where should we go?. Nat. Immunol. 2 (2001) 785-788
20. 3 immune-deviation. J. Neuroimmunol. 92 (1998) 113-121
21. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then Bergh F., Dose T., Wekerle H., and Hohlfeld R. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. 97 (2000) 7452-7457
22. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
23. Oger J., Gibb E., Basile E., and Aziz T. Anti-glatiramer acetate antibody levels in treated-multiple sclerosis patients. J. Mult. Scler.: Clin. Lab. Res. 11 32 (2004) 119
24. O'Gorman M., and Oger J. Regulation of in vitro PWM-induced IgG secretion in humans. Cell. Immunol. 118 2 (1989) 435-447
25. Stevenson V.L., Miller D.H., Rovaris M., Barkhof F., Brochet B., Dousset V., Dousset V., Filippi M., Montalban X., Polman C.H., Rovira A., de Sa J., and Thompson A.J. Primary and transitional progressive and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 52 (1999) 839-845
26. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., and Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1 (1971) 242-248
27. Teitelbaum D., Brenner T., Abramsky O., Aharoni R., Sela M., and Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult. Scler. 9 (2003) 592-599
28. Thompson A.J., Kermode A.G., MacManus D.G., Kendall B.E., Kingsley D.P., Moseley I.F., and McDonald W.I. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study. BMJ 300 (1990) 631-634
29. Thompson A.J., Polman C.H., Miller D.H., McDonald W.I., Brochet B., Filippi M., Montalban M., and De Sa J. Primary progressive multiple sclerosis. [Review]. Brain 120 (1997) 1085-1096
30. Wolinsky J., and for the PROMiSe Trial Study Group. The PROMiSe trial: baseline data review and progress report. Mult. Scler. 10 (2004) S65-S72
31. Ziemssen T., Kumpfel T., Klinkert W.E.F., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125 (2002) 2381-2391
32. Ziemssen T., Kumpfel T., Schneider H., Klinkert W.E.F., Neuhaus O., and Hohlfeld R. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: implications for multiple sclerosis therapy. J. Neuro Sci. 233 (2005) 109-112